To investigate the potential of EMP2 as a biomarker in patients with resistant disease, we evaluated its expression in a panel of women with BC pre- and post-standard chemotherapy, with an emphasis on understanding changes in its expression in TNBC. Here, EMP2 is linked to breast cancer.